Meet Trevena: CEO Gowen says product development on track
In an exclusive interview with The Fly, Trevena's (TRVN) CEO Maxine Gowen commented on the progress of two other product candidates being developed by the company, aside from its lead drug Oliceridine: "TRV250 is our investigational product with a potential first in class mechanism for the treatment of episodic migraine. Migraine is a condition for which the currently available treatments are really insufficient for millions of patients. We hope to submit an IND to the FDA later this year, and that should enable us to start clinical trials next year. So that's on track. '734, which is our investigational product for oral treatment of moderate to severe acute pain has completed its Phase 1 trials. While it's related to Oliceridine, it does have a different chemical structure and we will be looking to reach different clinical endpoints because this is now for acute and chronic pain taken orally, and the unmet needs for chronic pain are rather different from those for acute hospital pain. Because commercialization of '734 for chronic pain really isn't an ideal fit for our stated hospital and specialist focus, we think that it does make sense to evaluate partnering opportunities now. So that is still our plan." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.